 Lexaria Bioscience Corp NASDAQ: LEXX has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol CBD. The data showed that after a single day of dosing, the processed CBD reduced arterial stiffness, potentially broadening its application to the treatment of cardiovascular and other disease states beyond hypertension. 